VEGF-targeted therapy: mechanisms of anti-tumour activity

By L. Ellis, D. Hicklin. Nature Reviews. Cancer, 2008

1,684 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/1637644ee8c9504d3ddfd2e1237bde76f892f303

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. A. Adamis
2. Alicia S. Chung
3. J. Joyce
4. N. Ferrara
5. J. Pollard
6. Xiumin Wu
7. Cuiling Zhong
8. John Lee

In Molecular Biology

1. J. Joyce
2. A. Adamis
3. N. Ferrara
4. Alicia S. Chung
5. Xiumin Wu
6. Cuiling Zhong
7. John Lee
8. S. Ostrand-Rosenberg

In Oncology

1. J. Joyce
2. J. Pollard
3. S. Ostrand-Rosenberg
4. A. Adamis
5. N. Ferrara
6. P. Sinha
7. N. Vasudev
8. Alicia S. Chung

Citations in the corpus

• Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma (2011, background): “In addition to a lack of robust clinical data, the cellular and molecular consequences of anti-VEGF treatment have not been outlined (12).”
• Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. (2010, background): “In addition to antiangiogenic effects, VEGF targeting may produce clinical benefit through other mechanisms, including direct action against tumor cells.(8) The humanized, antiVEGF monoclonal antibody bevacizumab (Avastin; F.”
• Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions (2014, background): “Based on these data it has been proposed that inhibition of VEGF signalling in tumour cells may, at least in part, be mediated by direct activity against tumour cells [4].”
• Antibodies and cancer therapy: versatile platforms for cancer immunotherapy (2010, neutral): “Bevacizumab (Avastin; Genentech), a VEGFA-specific humanized monoclonal antibody, blocks binding of VEGF to its receptor and is approved for the treatment of breast, colorectal and non-small-cell lung cancer in combination with cytotoxic chemotherap”
• Targeting the tumour vasculature: insights from physiological angiogenesis (2010, background): “The anti-angiogenic agents that have so far been approved by the US Food and Drug Administration (FDA) as therapies for cancer or neovascular age-related macular degeneration (AMD) inhibit the VEGF pathway”
• Nanomedicine in cancer therapy (2023, background): “49,88 It has been shown that VEGF 121 - conjugated mesoporous silica nanoparticle could selectively deliver sunitinib, a potent receptor tyrosine kinase inhibitor, to tumor blood vessels in human U87MG glioblastoma-bearing mice by targeting VEGFR2, and exhibited superior anti-tumor ef fi cacy…”
• Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer (2009, background): “The nonimmune mechanisms include the following: 1) the production of reactive oxygen species (ROS)(3) such as peroxynitrites, which cause DNA mutations that contribute to genetic instability and the proliferation of malignant cells (2); 2) the production of proangiogenic factors such as vascular end”
• Ten years of anti-vascular endothelial growth factor therapy (2016, background): “Accordingly, several strategies to inhibit the VEGFA–VEGFR signalling pathway for the treatment of cancer have been explored 57,58 .”
• PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. (2009, background): “Targeting VEGF-A, in combination with chemotherapy, is efficacious in treating several human tumors (Ellis and Hicklin, 2008; Ferrara and Kerbel, 2005; Kerbel, 2008).”
• Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. (2016, background): “A classic example of the latter is anti-VEGF-therapy: monoclonal antibodies targeting VEGF (bevacizumab) or small molecule inhibitors targeting the VEGF receptor have shown clinical benefit in advanced cancer (Ellis & Hicklin, 2008).”
• Microenvironmental regulation of metastasis (2009, background): “Several Vegf antagonists have been approved by the US Food and Drug Administratio”